Windtree Therapeutics Inc

NASDAQ:WINT  
6.63
+0.01 (+0.15%)
Products, Other Pre-Announcement

Windtree Says FDA Acceptance Of Ind Application For A Phase 2 Clinical Trial Studying Kl4 Surfactant In Acute Lung Injury In Adults With Covid-19

Published: 09/29/2020 11:44 GMT
Windtree Therapeutics Inc (WINT) - Windtree Announces FDA Acceptance of Ind Application for a Phase 2 Clinical Trial Studying Kl4 Surfactant in Acute Lung Injury in Adults With Covid-19.
Windtree Therapeutics Inc - Sees Potential Expanded Covid-19 Program As Next Step.
Windtree Therapeutics Inc - Plans to Start Initial Covid-19 Phase 2 Study Within Next Several Weeks.
Windtree - If Initial Phase 2 Study Results Show Adequate Safety & Efficacy Under Covid-19 Program, Would Plan to Initiate 2 Additional Clinical Trials.